Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.


TSXV:EVMT - Post by User

Comment by zxcvbnnmon Jun 28, 2018 1:27pm
28 Views
Post# 28245905

RE:RE:RE:RE:RE:RE:RE:RE:Maybe a transaction will be announced soon

RE:RE:RE:RE:RE:RE:RE:RE:Maybe a transaction will be announced soonGood question. 

I agree that if the strategic review process for the loan division turns out to be not successful, the best way to do is to return the cash book of the loan division to shareholders and then wind up such division.

The billing division could be then operated as a stand-alone entity if management does see the growth potential as supported by the new Collector Automation Technology. But since there have been offers to acquire the billing division, it could be also sold if in reality the growth potential is not as good as expected. 

In any case, by simple maths, the company should be worth around 60 cents. The NAV of the company at 37.5 cents per share plus the billing division valued at 22 cents per share (assuming a $10M valuation). 
Bullboard Posts